|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCBL2 |
Gene summary for CCBL2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCBL2 | Gene ID | 56267 |
| Gene name | kynurenine aminotransferase 3 | |
| Gene Alias | CCBL2 | |
| Cytomap | 1p22.2 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | B4DW13 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 56267 | CCBL2 | P74T-E | Human | Esophagus | ESCC | 2.44e-20 | 4.92e-01 | 0.1479 |
| 56267 | CCBL2 | P75T-E | Human | Esophagus | ESCC | 6.62e-20 | 3.42e-01 | 0.1125 |
| 56267 | CCBL2 | P76T-E | Human | Esophagus | ESCC | 3.52e-19 | 3.71e-01 | 0.1207 |
| 56267 | CCBL2 | P79T-E | Human | Esophagus | ESCC | 9.02e-11 | 2.44e-01 | 0.1154 |
| 56267 | CCBL2 | P80T-E | Human | Esophagus | ESCC | 3.61e-26 | 6.26e-01 | 0.155 |
| 56267 | CCBL2 | P82T-E | Human | Esophagus | ESCC | 2.06e-06 | 3.87e-01 | 0.1072 |
| 56267 | CCBL2 | P83T-E | Human | Esophagus | ESCC | 2.18e-14 | 3.42e-01 | 0.1738 |
| 56267 | CCBL2 | P84T-E | Human | Esophagus | ESCC | 1.67e-05 | 2.67e-01 | 0.0933 |
| 56267 | CCBL2 | P89T-E | Human | Esophagus | ESCC | 4.86e-05 | 3.69e-01 | 0.1752 |
| 56267 | CCBL2 | P91T-E | Human | Esophagus | ESCC | 2.10e-19 | 1.10e+00 | 0.1828 |
| 56267 | CCBL2 | P94T-E | Human | Esophagus | ESCC | 6.09e-07 | 5.41e-01 | 0.0879 |
| 56267 | CCBL2 | P104T-E | Human | Esophagus | ESCC | 1.40e-05 | 3.53e-01 | 0.0931 |
| 56267 | CCBL2 | P107T-E | Human | Esophagus | ESCC | 3.84e-08 | 1.99e-01 | 0.171 |
| 56267 | CCBL2 | P126T-E | Human | Esophagus | ESCC | 4.97e-07 | 3.67e-01 | 0.1125 |
| 56267 | CCBL2 | P127T-E | Human | Esophagus | ESCC | 1.19e-14 | 2.57e-01 | 0.0826 |
| 56267 | CCBL2 | P128T-E | Human | Esophagus | ESCC | 2.22e-25 | 6.19e-01 | 0.1241 |
| 56267 | CCBL2 | P130T-E | Human | Esophagus | ESCC | 1.85e-18 | 4.30e-01 | 0.1676 |
| 56267 | CCBL2 | C04 | Human | Oral cavity | OSCC | 4.45e-04 | 3.51e-01 | 0.2633 |
| 56267 | CCBL2 | C21 | Human | Oral cavity | OSCC | 5.34e-12 | 5.16e-01 | 0.2678 |
| 56267 | CCBL2 | C30 | Human | Oral cavity | OSCC | 3.75e-13 | 8.13e-01 | 0.3055 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |